Similar to the in vivo data, the ex-vivo data at 24 h demonstrated a three- and six-fold increase in brain tumour signal for the anti-IGFBP7 sdAb compared with the competitively blocked anti-IGFBP7 sdAb-Cy5.5 and NC sdAb-Cy5.5, respectively (Figure 3D). Here, IGFBP7 is linked to brain neoplasm.